[go: up one dir, main page]

JO3003B1 - مركب أيميدازو [4، 5 -c ] كينولين-2- واحد واستخدامه كمثبط كيناز PI3/mtor - Google Patents

مركب أيميدازو [4، 5 -c ] كينولين-2- واحد واستخدامه كمثبط كيناز PI3/mtor

Info

Publication number
JO3003B1
JO3003B1 JOP/2011/0389A JOP20110389A JO3003B1 JO 3003 B1 JO3003 B1 JO 3003B1 JO P20110389 A JOP20110389 A JO P20110389A JO 3003 B1 JO3003 B1 JO 3003B1
Authority
JO
Jordan
Prior art keywords
imidazo
quinoline
kinase inhibitor
mtor kinase
mtor
Prior art date
Application number
JOP/2011/0389A
Other languages
English (en)
Inventor
Anthony Barda David
Margaret Mader Mary
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Application granted granted Critical
Publication of JO3003B1 publication Critical patent/JO3003B1/ar

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

يوفِّر الاختراع الحالي مركب إيميدازو [4،5-c]كوينولين-2-ون، أو ملح مقبول صيدلياً منه، والذي يثبَّط كلاً من PI3K وmTOR، لذا فهو يعد مفيداً في علاج السرطان.
JOP/2011/0389A 2011-01-14 2011-12-20 مركب أيميدازو [4، 5 -c ] كينولين-2- واحد واستخدامه كمثبط كيناز PI3/mtor JO3003B1 (ar)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161432958P 2011-01-14 2011-01-14

Publications (1)

Publication Number Publication Date
JO3003B1 true JO3003B1 (ar) 2016-09-05

Family

ID=45531593

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2011/0389A JO3003B1 (ar) 2011-01-14 2011-12-20 مركب أيميدازو [4، 5 -c ] كينولين-2- واحد واستخدامه كمثبط كيناز PI3/mtor

Country Status (39)

Country Link
US (2) US8440829B2 (ar)
EP (1) EP2663564B1 (ar)
JP (1) JP5891247B2 (ar)
KR (1) KR101561360B1 (ar)
CN (1) CN103282364B (ar)
AR (1) AR084551A1 (ar)
AU (1) AU2012205619B2 (ar)
BR (1) BR112013017672A2 (ar)
CA (1) CA2824760C (ar)
CL (1) CL2013002005A1 (ar)
CO (1) CO6731133A2 (ar)
CR (1) CR20130289A (ar)
CY (1) CY1116007T1 (ar)
DK (1) DK2663564T3 (ar)
DO (1) DOP2013000158A (ar)
EA (1) EA022163B1 (ar)
EC (1) ECSP13012764A (ar)
ES (1) ES2531891T3 (ar)
GT (1) GT201300180A (ar)
HR (1) HRP20150135T1 (ar)
HU (1) HUE024426T2 (ar)
IL (1) IL227165A (ar)
JO (1) JO3003B1 (ar)
ME (1) ME02019B (ar)
MX (1) MX2013008185A (ar)
MY (1) MY164705A (ar)
PE (1) PE20140864A1 (ar)
PH (1) PH12013501493A1 (ar)
PL (1) PL2663564T3 (ar)
PT (1) PT2663564E (ar)
RS (1) RS53828B1 (ar)
SG (1) SG191744A1 (ar)
SI (1) SI2663564T1 (ar)
SV (1) SV2013004496A (ar)
TN (1) TN2013000237A1 (ar)
TW (1) TWI518086B (ar)
UA (1) UA109921C2 (ar)
WO (1) WO2012097039A1 (ar)
ZA (1) ZA201304757B (ar)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3003B1 (ar) 2011-01-14 2016-09-05 Lilly Co Eli مركب أيميدازو [4، 5 -c ] كينولين-2- واحد واستخدامه كمثبط كيناز PI3/mtor
US9050345B2 (en) 2013-03-11 2015-06-09 Bristol-Myers Squibb Company Pyrrolotriazines as potassium ion channel inhibitors
US20160264570A1 (en) * 2013-11-15 2016-09-15 The United States Of America, As Represented By The Secretary, Department Of Health And Human Serv Method of blocking transmission of malarial parasite
TWI609687B (zh) 2015-04-14 2018-01-01 美國禮來大藥廠 平滑肌肉瘤之標靶性治療
TW201703769A (zh) 2015-05-08 2017-02-01 美國禮來大藥廠 用於癌症的組合療法
GB201516504D0 (en) * 2015-09-17 2015-11-04 Astrazeneca Ab Imadazo(4,5-c)quinolin-2-one Compounds and their use in treating cancer
CA3005358A1 (en) * 2015-12-15 2017-06-22 Eli Lilly And Company Combination therapy for cancer
WO2017156350A1 (en) 2016-03-09 2017-09-14 K-Gen, Inc. Methods of cancer treatment
CN109310685B (zh) * 2016-04-12 2021-10-29 伊莱利利公司 用于治疗癌症的notch和pi3k/mtor抑制剂的组合疗法
RU2747788C2 (ru) * 2016-04-12 2021-05-14 Эли Лилли Энд Компани Комбинированная терапия ингибиторами notch и cdk4/6 для лечения рака
IL263110B (en) 2016-05-20 2022-07-01 Lilly Co Eli Combined treatment of notch and pd-1 or pd-l1 inhibitors
WO2018017410A1 (en) 2016-07-22 2018-01-25 Eli Lilly And Company Combination therapy of abemaciclib and a pi3 kinase/mtor dual inhibitor for use in the treatment of breast cancer
WO2018063873A1 (en) 2016-09-27 2018-04-05 Eli Lilly And Company Combination therapy of abemaciclib and a pi3 kinase/mtor dual inhibitor for use in the treatment of pancreatic cancer
CA3039405A1 (en) 2016-10-12 2018-04-19 Eli Lilly And Company Targeted treatment of mature t-cell lymphoma
IL268349B2 (en) 2017-02-17 2024-08-01 Hutchinson Fred Cancer Res Combination therapies for treatment of bcma-related cancers and autoimmune disorders
JP7233425B2 (ja) 2017-11-06 2023-03-06 ジュノー セラピューティクス インコーポレイテッド 細胞療法とガンマセクレターゼ阻害剤との組み合わせ
US10596165B2 (en) 2018-02-12 2020-03-24 resTORbio, Inc. Combination therapies
CN110386932A (zh) 2018-04-20 2019-10-29 艾科思莱德制药公司 用于抗肿瘤疗法中的双重atm和dna-pk抑制剂
SI3813946T1 (sl) 2018-06-15 2024-07-31 Janssen Pharmaceutica Nv Analogi rapamicina in njihove uporabe
WO2020081329A1 (en) * 2018-10-18 2020-04-23 Camp4 Therapeutics Corporation Methods and compositions for modulating pcsk9 and angptl3 expression
BR112022010754A2 (pt) 2019-12-05 2022-08-23 Anakuria Therapeutics Inc Análogos de rapamicina e usos dos mesmos
CN116056698B (zh) * 2020-09-21 2024-11-19 威尚（上海）生物医药有限公司 具有血脑屏障穿透能力的取代的1-(3,3-二氟哌啶-4-基)-咪唑并[4,5-c]喹啉-2-酮化合物
EP3992191A1 (en) 2020-11-03 2022-05-04 Deutsches Krebsforschungszentrum Imidazo[4,5-c]quinoline compounds and their use as atm kinase inhibitors
AU2022421244A1 (en) 2021-12-22 2024-07-11 Camp4 Therapeutics Corporation Modulation of gene transcription using antisense oligonucleotides targeting regulatory rnas

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0211649D0 (en) 2002-05-21 2002-07-03 Novartis Ag Organic compounds
AR046845A1 (es) * 2003-11-21 2005-12-28 Novartis Ag Derivados de 1h-imidazo[4,5-c]quinolina para tratamiento de enfermedades dependientes de las proteino-quinasas
AU2004295061B2 (en) 2003-11-21 2008-11-20 Novartis Ag 1H-imidazoquinoline derivatives as protein kinase inhibitors
AU2006216798A1 (en) * 2005-02-23 2006-08-31 Coley Pharmaceutical Group, Inc. Hydroxyalkyl substituted imidazoquinoline compounds and methods
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
KR20080083270A (ko) 2005-11-04 2008-09-17 콜레이 파마시티컬 그룹, 인코포레이티드 하이드록시 및 알콕시 치환된 1에이치 이미다조퀴놀린 및방법
WO2007106854A2 (en) 2006-03-15 2007-09-20 Coley Pharmaceutical Group, Inc. Hydroxy and alkoxy substituted 1h-imidazonaphthyridines and methods
EP2356120B1 (en) * 2008-09-30 2016-10-12 Pfizer Inc. Imidazo[1,5]naphthyridine compounds, their pharmaceutical use and compositions
WO2010139731A1 (en) 2009-06-04 2010-12-09 Novartis Ag 1H-IMIDAZO[4,5-c]QUINOLINONE DERIVATIVES
CN102803259A (zh) * 2009-06-04 2012-11-28 诺瓦提斯公司 用于治疗增殖性疾病的1H-咪唑并[4,5-c]喹啉酮化合物
JP2012532187A (ja) * 2009-06-30 2012-12-13 ピラマル・ライフ・サイエンシーズ・リミテッド イミダゾ［４，５−ｃ］キノリン誘導体ならびに腫瘍および／または炎症の治療におけるそれらの使用
CA2819955A1 (en) * 2010-12-06 2012-06-14 Piramal Enterprises Limited Substituted imidazoquinoline derivatives
JO3003B1 (ar) 2011-01-14 2016-09-05 Lilly Co Eli مركب أيميدازو [4، 5 -c ] كينولين-2- واحد واستخدامه كمثبط كيناز PI3/mtor

Also Published As

Publication number Publication date
US20130237562A1 (en) 2013-09-12
RS53828B1 (sr) 2015-06-30
TN2013000237A1 (en) 2014-11-10
UA109921C2 (uk) 2015-10-26
ME02019B (me) 2015-05-20
HRP20150135T1 (xx) 2015-03-13
CO6731133A2 (es) 2013-08-15
ECSP13012764A (es) 2013-09-30
SI2663564T1 (sl) 2015-01-30
DOP2013000158A (es) 2013-11-30
ES2531891T3 (es) 2015-03-20
KR20130116302A (ko) 2013-10-23
IL227165A (en) 2016-06-30
SG191744A1 (en) 2013-08-30
CR20130289A (es) 2013-10-07
CN103282364B (zh) 2015-06-17
EP2663564A1 (en) 2013-11-20
US20120184577A1 (en) 2012-07-19
JP5891247B2 (ja) 2016-03-22
HK1188454A1 (en) 2014-05-02
AU2012205619A1 (en) 2013-06-27
BR112013017672A2 (pt) 2018-09-18
CL2013002005A1 (es) 2013-12-27
DK2663564T3 (en) 2015-01-12
US8658668B2 (en) 2014-02-25
EA201390823A1 (ru) 2013-12-30
KR101561360B1 (ko) 2015-10-16
PH12013501493A1 (en) 2021-06-02
MX2013008185A (es) 2013-08-21
CN103282364A (zh) 2013-09-04
NZ611541A (en) 2015-02-27
CY1116007T1 (el) 2017-01-25
PE20140864A1 (es) 2014-07-19
TWI518086B (zh) 2016-01-21
EA022163B1 (ru) 2015-11-30
ZA201304757B (en) 2014-12-23
PL2663564T3 (pl) 2015-05-29
US8440829B2 (en) 2013-05-14
HUE024426T2 (en) 2016-01-28
AR084551A1 (es) 2013-05-22
CA2824760A1 (en) 2012-07-19
CA2824760C (en) 2016-03-15
MY164705A (en) 2018-01-30
SV2013004496A (es) 2017-11-07
PT2663564E (pt) 2015-02-24
EP2663564B1 (en) 2014-12-17
WO2012097039A1 (en) 2012-07-19
JP2014502638A (ja) 2014-02-03
AU2012205619B2 (en) 2015-05-21
GT201300180A (es) 2014-04-08
TW201307343A (zh) 2013-02-16

Similar Documents

Publication Publication Date Title
JO3003B1 (ar) مركب أيميدازو [4، 5 -c ] كينولين-2- واحد واستخدامه كمثبط كيناز PI3/mtor
PH12019501321B1 (en) Use of pyrazolopyrimidine derivatives for the treatment of pi3k-delta related disorders
EA201490194A1 (ru) Комбинированная терапия, включающая ингибитор cdk4/6 и ингибитор pi3k для применения в лечении рака
MX378263B (es) Terapia de combinación para el tratamiento del cáncer.
PH12018501807A1 (en) Pyrazolopyrrolidine derivatives and their use in the treatment of diseas
CL2013002177A1 (es) Compuestos derivados de 9h-purinas y 7h-pirrolo[2,3-d]-pirimidinas sustituidas, inhibidores de la pi3k de clase i y/o mtor; su composicon farmaceutica; su combinacion farmaceutica; y su uso en el tratamiento o la prevencion del cancer o trastornos neurodegenerativos.
SA515360469B1 (ar) مركبات حلقية غير متجانسة لتثبيط إنزيم جلوتاميناز والطرق الخاصة باستخدامها
WO2012068106A3 (en) Benzoxazepines as inhibitors of pi3k/mtor and methods of their use and manufacture
MX360634B (es) Inhibidores de 3-haloalilamina sustituidos de ssao y uso de los mismos.
PH12014501986B1 (en) 2-amino, 6-phenyl substituted pyrido [2,3-d] pyrimidine derivatives useful as raf kinase inhibitors
HK1216176A1 (zh) 用於治疗增殖性和自身免疫疾病的非对称吡咯并苯并二氮杂卓二聚物
MX2015017964A (es) Inhibidores de bromodominio.
MX2013005826A (es) Benzoxazepinas como inhibidores de fosfatidilinositol 3-cinasa/objetivo de rapamicina en mamiferos (p13k/mtor) y metodos de uso y fabricacion.
TR201905814T4 (tr) Jak inhibitörü olarak bipirazol tuzu.
WO2012068096A3 (en) Benzoxazepines as inhibitors of pi3k/mtor and methods of their use and manufacture
MX2015016421A (es) Derivados de pirazolo-pirrolidin-4-ona como inhibidores de bet y su uso en el tratamiento de enfermedades.
MX2010010300A (es) Formas de sal de inhibidores del objetivo de rapamicina en mamiferos.
BR112014029705A2 (pt) composto ou sal, medicamento, métodos para inibir quinase de janus em um mamífero, e para a profilaxia ou tratamento de doenças autoimunes, e, uso de um composto ou sal
EA201591483A1 (ru) Производные имидазо[4,5-с]пиридина и пирроло[2,3-с]пиридина в качестве ингибиторов ssao
MX2015016425A (es) Derivados de pirazolo-pirrolidin-4-ona y su uso en el tratamiento de enfermedades.
PH12016502353A1 (en) Pharmaceutical composition
TW201613577A (en) Pharmaceutical combinations
MX2013005819A (es) Benzoxazepinas como inhibidores de 3-cinasa/objetivo mamífero de rapamicina (pi3k/mtor) metodos de uso y fabricacion.
WO2014160177A3 (en) Quinazoline inhibitors of pi3k
TH149217A (th) สารประกอบอิมิดาโซล[4,5-c]ควินอลิน-2-โอน และการใช้ของมันในรูปตัวยับยั้งคู่สำหรับ Pl3 คิเนส/MTOR